New study tracks oxytocin spikes in MDMA therapy trials

The psychoactive drug MDMA temporarily increases levels of the social hormone oxytocin in human subjects, with levels peaking a few hours after use. These findings might help researchers time therapeutic interventions during clinical trials for psychiatric conditions like post-traumatic stress disorder. The research was published in Neuroscience and Biobehavioral Reviews.

The drug 3,4-methylenedioxymethamphetamine, commonly known as MDMA, is classified as an entactogen. This designates it as a psychoactive substance that heavily alters emotional processing. People who take the substance often report enhanced feelings of closeness, empathy, and social unity.

In recent years, MDMA has become the subject of clinical trials for treating post-traumatic stress disorder, commonly called PTSD. Therapists suggest that the drug helps patients build an emotional bond with their doctors. It reduces anxiety related to social interactions and helps people process perceived emotional threats.

Researchers suspect a primary biological mechanism behind these prosocial effects is the release of oxytocin. Oxytocin is a chemical messenger produced in the hypothalamus, a region deep within the brain. It acts as both a local brain signaling molecule and a hormone that circulates throughout the body.

The hormone is best known for its role in childbirth and lactation, but it also regulates social behaviors. Elevated levels of oxytocin are linked to increased empathy, generosity, and trust, particularly among people within the same social group.

Free daily newsletter

MDMA initiates its effects by causing the brain to release a flood of monoamines. These are chemical messengers that include serotonin, dopamine, and norepinephrine.

The sudden surge of serotonin activates specific receptors on neurons in the hypothalamus. Animal models demonstrate that this receptor activation directly triggers the release of oxytocin into the bloodstream and central nervous system.

Medical professionals have tried administering oxytocin directly via nasal sprays to treat social anxiety and similar conditions. However, the nasal spray has a very short active period in the bloodstream, disappearing in just a few minutes.

MDMA, by contrast, has a much longer active window. It promotes a robust release of the body’s own naturally produced oxytocin. This creates a sustained social effect that is better suited for long psychotherapy sessions.

While individual studies have shown that MDMA triggers the release of oxytocin, results have varied widely. Lead author Anna Vaslavski, a researcher at Bar-Ilan University, and her colleagues noticed a gap in the literature. No previous research had systematically gathered and analyzed these disparate studies to figure out exactly how the drug influences oxytocin levels across different times, doses, and demographic groups.

To find answers, the research team conducted a meta-analysis. This is a statistical technique that pools data from multiple independent studies to identify overall trends. The team searched academic databases to find peer-reviewed studies that administered MDMA to human subjects and measured their oxytocin levels.

They identified ten qualifying studies containing a total of 39 effect size estimates. The original studies used varying doses of MDMA, ranging from 75 to 150 milligrams. The researchers also measured oxytocin from blood or urine samples at different time intervals.

The team analyzed this pooled data, looking specifically at three modifying variables. They tested whether the amount of the drug, the time of measurement, or the sex of the participants altered the amount of oxytocin released.

Time emerged as a modifying factor, showing a curvilinear relationship with hormone levels. After a person took MDMA, their oxytocin levels rose steadily. The levels reached their highest point between 150 and 200 minutes after administration.

Following this peak, oxytocin concentrations began to decline. Some studies noted that levels remained slightly elevated above their baseline even five hours after the drug was taken.

The analysis did not find a statistically significant relationship between the dose of MDMA and the resulting oxytocin levels. The varied dosing strategies used in the original ten studies might explain this lack of an effect. Some studies gave all participants a flat dose, while others adjusted the amount based on a person’s body weight.

The team also found a slight trend regarding the sex of the participants. The results suggested that studies with a higher proportion of female subjects tended to record smaller increases in oxytocin. However, this finding was not statistically significant and requires more targeted testing to confirm.

Readers should exercise caution when interpreting blood or urine oxytocin levels as a direct reflection of brain activity. Oxytocin in the bloodstream does not easily cross the blood-brain barrier, meaning peripheral levels might not perfectly mirror the amounts acting directly on brain circuits.

Still, recent physiological studies suggest that circulating oxytocin can influence the brain indirectly. The hormone can stimulate the vagus nerve, a major neural pathway connecting the body’s internal organs to the brainstem. This vagal pathway might carry the social and emotional signals generated by peripheral oxytocin into the central nervous system.

The meta-analysis also revealed a high degree of unexplained variance among the ten studies. The statistical models showed that differences in time, dose, and sex only accounted for about a quarter of the variation in the results. This indicates that other unmeasured biological factors are influencing how much oxytocin the body releases in response to MDMA.

The potential difference in how males and females respond to the drug might be tied to estrogen. Estrogen is known to regulate how sensitive cells are to oxytocin.

Because the analysis relied on existing published data, the research team could not isolate female-only groups or control for the use of hormonal birth control. These missing details leave the exact nature of the sex difference an open question. Differences in body mass index or the menstrual cycle could potentially alter how a person reacts to the drug.

Methodological differences in how the original researchers processed their biological samples might also have skewed the overall numbers. Oxytocin levels can appear vastly different depending on whether researchers use advanced extraction techniques to isolate the hormone from blood plasma.

Moving forward, scientists need to standardize how they administer MDMA and measure oxytocin. Implementing consistent dosing based on body weight and utilizing uniform extraction methods will yield more reliable data.

The researchers also noted evidence of publication bias in the available literature. Small studies with larger margins of error tended to report disproportionately high oxytocin effects. Conducting studies with a large sample size will help correct this imbalance and verify the true strength of the drug’s impact on the hormonal system.

The study, “The effect of MDMA administration on oxytocin concentration levels: systematic review and a multilevel meta-analysis in humans,” was authored by Anna Vaslavski, Anna Harwood-Gross, Salomon Israel, and Leehe Peled-Avron.